Tubulis
Pamela Trail is a leading expert in oncology research and has more than 30 years of experience in the biotechnology and pharmaceutical industry developing ADCs, immunomodulatory antibodies, bispecific antibodies and small molecules.
Between 2017 and 2019, she held the position Chief Scientific Officer at Molecular Partners. Prior, she served as Vice President Oncology Strategy and Program Direction at Regeneron Pharmaceuticals. She also held the positions of Vice President of Oncology Research at MedImmune, Chief Scientific Officer at Seattle Genetics, Global Vice President of Oncology Research at Bayer Healthcare, and Director of Oncology Research at Bristol-Myers Squibb. Dr. Tail has authored over 45 publications and holds multiple issued patents. Dr. Trail has served as a Board Member of BerGen Bio, Nilogen Oncosystems, and Neoantigenics.
She holds a PhD in Immunology from University of Connecticut.
This person is not in the org chart
This person is not in any offices
Tubulis
2 followers
Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Their goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. They will advance a range of conjugates, unlimited by indication, using their own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.